WO2005018436A8 - Methods for the diagnosis, prognosis and treatment of metabolic syndrome - Google Patents

Methods for the diagnosis, prognosis and treatment of metabolic syndrome

Info

Publication number
WO2005018436A8
WO2005018436A8 PCT/US2004/027758 US2004027758W WO2005018436A8 WO 2005018436 A8 WO2005018436 A8 WO 2005018436A8 US 2004027758 W US2004027758 W US 2004027758W WO 2005018436 A8 WO2005018436 A8 WO 2005018436A8
Authority
WO
WIPO (PCT)
Prior art keywords
metabolic syndrome
prognosis
diagnosis
treatment
methods
Prior art date
Application number
PCT/US2004/027758
Other languages
French (fr)
Other versions
WO2005018436A3 (en
WO2005018436A2 (en
Inventor
Lindsay A Farrer
Diego F Wyszynski
Original Assignee
Univ Boston
Lindsay A Farrer
Diego F Wyszynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Boston, Lindsay A Farrer, Diego F Wyszynski filed Critical Univ Boston
Publication of WO2005018436A2 publication Critical patent/WO2005018436A2/en
Publication of WO2005018436A8 publication Critical patent/WO2005018436A8/en
Publication of WO2005018436A3 publication Critical patent/WO2005018436A3/en
Priority to US11/359,346 priority Critical patent/US20060211020A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The present invention provides methods for detecting susceptibility to metabolic syndrome. In particular, the presence of differences in at least one of the following genes; microsomal triglyceride transfer protein (MTP), fatty acid binding protein 2 (FABP2), annexin A5 (ANXA5), pyruvate dehydrogenase (lipoamide) alpha 2 (PDHA2), CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) I (CDS 1), and glycerol kinase 2 (GK2) serves as a prognostic and diagnostic indicator of metabolic syndrome. Furthermore, metabolic syndrome can be treated by regulating the levels of MTP, FABP2, ANXA5, PDHA2, CDS1, and GK2.
PCT/US2004/027758 2003-08-26 2004-08-26 Methods for the diagnosis, prognosis and treatment of metabolic syndrome WO2005018436A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/359,346 US20060211020A1 (en) 2003-08-26 2006-02-22 Methods for the diagnosis, prognosis and treatment of metabolic syndrome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49808203P 2003-08-26 2003-08-26
US60/498,082 2003-08-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/359,346 Continuation US20060211020A1 (en) 2003-08-26 2006-02-22 Methods for the diagnosis, prognosis and treatment of metabolic syndrome

Publications (3)

Publication Number Publication Date
WO2005018436A2 WO2005018436A2 (en) 2005-03-03
WO2005018436A8 true WO2005018436A8 (en) 2005-06-23
WO2005018436A3 WO2005018436A3 (en) 2005-08-18

Family

ID=34216160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/027758 WO2005018436A2 (en) 2003-08-26 2004-08-26 Methods for the diagnosis, prognosis and treatment of metabolic syndrome

Country Status (2)

Country Link
US (1) US20060211020A1 (en)
WO (1) WO2005018436A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5697296B2 (en) 2004-03-05 2015-04-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Method for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia with minimal side effects
US10544459B2 (en) 2004-12-08 2020-01-28 Cedars-Sinai Medical Center Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
ATE477497T1 (en) * 2004-12-08 2010-08-15 Cedars Sinai Medical Center METHOD FOR DIAGNOSIS OF CROHN'S DISEASE
CA2592176A1 (en) * 2004-12-09 2006-06-15 Perlegen Sciences, Inc. Markers for metabolic syndrome obesity and insulin resistance
EP1951224A2 (en) * 2005-10-18 2008-08-06 Aegerion Pharmaceuticals Methods for treating disorders associated with hyperlipidemia in a mammal
US20090042835A1 (en) * 2006-06-02 2009-02-12 Davis Roger A Compositions and methods for ameliorating hyperlipidemia
WO2008079398A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US8153443B2 (en) * 2007-05-10 2012-04-10 Cedars-Sinai Medical Center Characterization of the CBir1 antigenic response for diagnosis and treatment of Crohn's disease
AT505727B1 (en) * 2007-09-04 2009-06-15 Univ Innsbruck METHOD FOR DIAGNOSIS OF METABOLIC SYNDROME
BRPI0821272A2 (en) * 2007-12-18 2015-06-16 Athera Biotechnologies Ab Methods for the treatment of vascular dysfunction, to reduce ischemic pain and for the treatment, prevention or reduction of risk of onset of a vascular disease, and annexin a5 or functional analogue or variant thereof
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US20130059778A1 (en) * 2010-03-15 2013-03-07 Vann Bennett Identification of a Genetic Risk Factor for Diabetes
JP6671276B2 (en) 2013-03-27 2020-03-25 セダーズ−シナイ メディカル センター Alleviation and recovery of fibrosis and inflammation by suppression of TL1A function and related signaling pathways
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
KR102464372B1 (en) 2016-03-17 2022-11-04 세다르스-신나이 메디칼 센터 Methods of diagnosing inflammatory bowel disease through rnaset2
CA3080818A1 (en) 2017-10-30 2019-05-09 Montreal Heart Institute Methods of treating elevated plasma cholesterol
WO2019140008A2 (en) * 2018-01-09 2019-07-18 The Regents Of The University Of California Methods for using dna methylation as a biomarker for identification and treatment of metabolic syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156510A (en) * 1997-12-02 2000-12-05 Gemini International Holdings Limited Polymorphisms in a microsatellite region of a glucocorticoid receptor gene
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia

Also Published As

Publication number Publication date
US20060211020A1 (en) 2006-09-21
WO2005018436A3 (en) 2005-08-18
WO2005018436A2 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
WO2005018436A8 (en) Methods for the diagnosis, prognosis and treatment of metabolic syndrome
Meier et al. Niche partitioning of diverse sulfur-oxidizing bacteria at hydrothermal vents
Ye et al. Dietary adaptation of FADS genes in Europe varied across time and geography
Westerholm et al. Detection of novel syntrophic acetate‐oxidizing bacteria from biogas processes by continuous acetate enrichment approaches
Rubino et al. Divergent functional isoforms drive niche specialisation for nutrient acquisition and use in rumen microbiome
Glaubitz et al. 13C‐isotope analyses reveal that chemolithoautotrophic Gamma‐and Epsilonproteobacteria feed a microbial food web in a pelagic redoxcline of the central Baltic Sea
Finney et al. Predisposition to neoplastic transformation caused by gene replacement of H-ras 1
Fischer et al. Adaptation to drought in two wild tomato species: the evolution of the Asr gene family
Schönhals et al. Identification and reproducibility of diagnostic DNA markers for tuber starch and yield optimization in a novel association mapping population of potato (Solanum tuberosum L.)
Grusz A current perspective on apomixis in ferns
Lee et al. Global gene expression responses to waterlogging in leaves of rape seedlings
Hodgins et al. Expression divergence is correlated with sequence evolution but not positive selection in conifers
Soto-Cerda et al. Genome-wide association analysis of mucilage and hull content in flax (Linum usitatissimum L.) seeds
NZ590750A (en) Methods and compositions for improving the production of products in microorganisms, especially clostridium phytofermentans
Hovav et al. A transcriptome profile for developing seed of polyploid cotton
Ono et al. Association of dietary and genetic factors related to one‐carbon metabolism with global methylation level of leukocyte DNA
MX2007009809A (en) Selection probe amplification.
NZ601079A (en) Methods and compositions for noninvasive prenatal diagnosis of fetal aneuploidies
DE602004012881D1 (en) Cst (compartmentalised self tagging)
WO2007082269A3 (en) Epsp synthase enzyme domains conferring glyphosate resistance
Scalfi et al. Micro-and macro-geographic scale effect on the molecular imprint of selection and adaptation in Norway spruce
Du et al. Complex evolution of S5, a major reproductive barrier regulator, in the cultivated rice Oryza sativa and its wild relatives
Zhang et al. Genetic analysis of central carbon metabolism unveils an amino acid substitution that alters maize NAD-dependent isocitrate dehydrogenase activity
Plötner et al. Chlorosis caused by two recessively interacting genes reveals a role of RNA helicase in hybrid breakdown in Arabidopsis thaliana
Pascual et al. Deciphering genetic diversity and inheritance of tomato fruit weight and composition through a systems biology approach

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 09/2005 UNDER (71) THE NAME SHOULD READ "THE TRUSTEES OF BOSTON UNIVERSITY"

WWE Wipo information: entry into national phase

Ref document number: 11359346

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11359346

Country of ref document: US

122 Ep: pct application non-entry in european phase